38: Drinking Water Source and Cigarette Smoking in Transitional Cell Carcinoma of the Bladder

2006

Management of bicalutamide induced gynaecomastia. A randomized study comparing therapy versus prophylaxis with tamoxifen.

2008

Introduction and Objective: Gynaecomastia is a potentially treatment limiting adverse event of antiandrogen monotherapy for prostate cancer. Tamoxifen has shown to be effective in therapy and prophylaxis of gynecomastia and breast pain. However, tamoxifene dosage and treatment duration are not established and debate still exists if prophylaxis is more effective than therapy at the early onset. This randomized study compared the prophylactic activity of tamoxifene at the dose of 10 mg with its therapeutic activity when given at the dose of 20 mg at the early appearance of gynecomastia in patients receiving bicalutamide 150 mg/d for prostate cancer. Methods: Between June 2005 and June 2007, 1…

Prediction by quantitative histology of pathological stage in prostate cancer.

2005

To find a predictor of extraprostatic extension in clinically localized prostate cancer (PCa), pre-operative ultrasound-guided prostate needle biopsies and clinico-pathological data were reviewed.One hundred and eighty-three consecutive patients who underwent radical retropubic prostatectomy for clinical T1-T2 PCa and serum PSA10 ng/ml were reviewed. Pre-operative biopsy was performed according to an extended protocol and whole-mount prostatectomy specimens were processed. The following biopsy variables were categorized to this analysis: Gleason score (or =6,6), TPC (or =20%;20%), GPC (or =50%;50%), cancer-positive cores (or =2;2), cancer-positive cores in both lateral portions (yes; no), P…

Multiplicity and history have a detrimental effect on survival in patients with T1G3 bladder tumors selected for conservative treatment.

2008

Purpose: In the absence of Tis tumor we assessed whether history and multiplicity have a detrimental effect on conservative treatment in carefully selected patients with T1G3 bladder carcinoma. Materials and Methods: Between January 1976 and December 1999, 165 select patients with T1G3 bladder tumors were conservatively treated with transurethral resection plus adjuvant intravesical therapy. Patients with concomitant or previous Tis, previous T1G3, tumor size greater than 3 cm and more than 3 lesions were excluded from analysis. Repeat transurethral resection was not routinely performed. However, cytology had to be negative for atypia before the start of adjuvant intravesical therapy. Resul…

Comments and Final Remarks

2020

In this study, the multi-criteria approach is used to obtain rankings for a number of Italian universities, according to certain curricular and job placement graduate characteristics.

Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study

2003

OBJECTIVE To present the long-term outcome of patients with locally advanced or metastatic prostate carcinoma treated by first-line antiandrogen monotherapy. PATIENTS AND METHODS From 1983 to 1990, 41 patients with advanced prostate carcinoma were treated with flutamide monotherapy until progression or the appearance of toxicity. Twenty-five patients (61%) had T3-T4N0M0 and 16 (39%) T2–4N0–3M1 prostate carcinoma. Consensus criteria were adopted to evaluate the response. Plasma testosterone and sexual function were recorded for the first 3 years. RESULTS Flutamide was administered for up to 147 months; seven patients (17%) interrupted the treatment because of toxicity. There was an objective…

About Overeducation and Mismatching

2020

Evidence from several developed economies has shown that skill mismatch and overeducation are widespread phenomena and that they typically affect about one-third of the higher educated employed population.

Is free/total PSA predictive of pathological stage and Gleason score in patients with prostate cancer and serum PSAor=10 ng/ml?

2005

<i>Introduction:</i> To evaluate whether percent free prostate-specific antigen (%-fPSA) could be predictive of pathological stage and Gleason score in patients with prostate cancer (PCa) and serum PSA of 10 ng/ml or less. <i>Materials and Methods:</i> In 100 patients with total PSA≤10 ng/ml who underwent radical retropubic prostatectomy as primary treatment of PCa, %-fPSA levels in organ-confined vs. non-organ-confined PCa and in patients with Gleason score ≤/>7 were compared. <i>Results:</i> 32 patients had an organ-confined and 68 a locally advanced PCa. Median %-fPSA level was 15%; Gleasonscore was <7 in 49 patients, equal to 7 in 40 and >7 i…

The Prognostic Value of P53 in Predicting of Bladder Carcinoma

2005

The prognostic value of p53 in predicting recurrence and progression of superficial transitional cell carcinoma of the bladder (TCCB) is still uncertain. Materials and methods P53 expression was retrospectively assessed in 160 patients. At a median follow-up of 45 months, (up to years) 84 patients (53%) recurred and 13 (8%) progressed. Adjuvant intravesical chemotherapy after TUR was adopted in 51 patients (32%). The correlations between p53 and G-grade, T-category, risk of recurrence and progression, and intravesical chemotherapy were investigated. Similarly, the correlations between variations in grade and stage at recurrence and modifications in p53 expression were also studied. Results…

Osservational Study on Early Diagnosis of Prostate Carcinoma in Sicily and Calabria

2004

The diagnosis of prostate carcinoma has been monitored in Sicily and Calabria for one year. Material e Methods Twenty-seven urological centres of Sicily and Calabria joined the study. Detailed informations about age, familiarity, PSA, Gleason score and TNM stage at diagnosis were centralized between november 2001 and november 2002. Results 721 patients have been recruited. The median age was 73 years. More than 80% of the patients were older than 65 years. Median PSA was 14 ng/ml. The clinical stage at diagnosis was T1c in 33% of patients and 67% had an organ confined prostate cancer (T1-T2). Familiarity was detected in 8% of cases. Age and PSA at diagnosis in these patients were similar t…

Conservative management of T1G3 transitional cell carcinoma of the bladder. Risk factor analysis in 165 selected patients

2003

INTRODUCTION AND OBJECTIVE: The management of TlG3 transitional cell carcinoma of the bladder (TCCB), is still controversial. Some Authors support an immediate radical cystectomy. BCG is considered the treatment of choice. Limited encouraging experiences are reported with intravesical chemotherapy. Objectives; Evaluating a selected population of 165 patients with TlG3 TCCB, in absence of Tis, treated conservatively with TUR plus adjuvant intravesical therapy. METHODS: Between January 1976 and December 1999, 165 patients with TlG3 bladder tumors were treated by TUR plus adjuvant intravesical therapy. Patients with previuos T1G3, Tis, more than 3 tumors or greater than 3 em were excluded. A s…

Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between…

2014

BACKGROUND Phytotherapy has been used to treat patients with lower urinary tract symptoms (LUTS). We evaluated the efficacy and tolerability of combination therapy between Serenoa Repens (SeR), Lycopene (Ly), and Selenium (Se) + tamsulosin versus single therapies. METHODS PROCOMB trial (ISRCTN78639965) was a randomized double-blinded, double-dummy multicenter study of 225 patients between 55 and 80 years old, PSA ≤ 4 ng/ml, IPSS ≥12, prostate volume ≤60 cc, Qmax ≤15 ml/sec, postvoid residual urine (PVR) <150 ml. Participants were randomized group A (SeR-Se-Ly), group B (tamsulosin 0.4 mg), group C (SeR-Se-Ly + tamsulosin 0.4 mg). The primary endpoints of the study were the reduction of IPSS…

A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.

2012

BACKGROUND: Tamoxifen (TAM) has been shown to be active against the bicalutamide-induced breast events (BEs) gynecomastia, and breast pain in patients with prostate cancer (PC). Optimal doses and schedules are not yet established. Debate still exists about whether prophylaxis with TAM is more effective than treatment of BEs when diagnosed. The results of a randomized study comparing TAM prophylaxis vs. TAM therapy are presented. METHODS: One hundred seventy-six patients with prostate cancer (PC) who were candidates for bicalutamide monotherapy were randomized to receive TAM 20 mg daily orally within 1 month from the onset of BEs (arm A) vs. TAM 10 mg daily starting simultaneously with bical…

Variations PSA Value in Patients Candidate to Biopsy of the Prostate

2005

Subclinical infections of the prostate can increase the prostate-specific antigen (PSA) values in patients with normal digital rectal examination. This study aimed to evaluate the role of short-term antimicrobial therapy in reducing the PSA value in patients as candidates for transrectal biopsy. Fifty-eight patients with negative digital rectal examination and PSA values between 4 and 20 ng/mL were included in the study. Antibiotics were administered to all patients for 3 weeks, and the PSA was reassessed 10 days after the end of the treatment. Patients were subsequently submitted to prostate biopsy. A reduction in PSA was detected in 34 patients (59%). Mean percentage reduction was 32%. I…

The genitourinary diseases health-care among patients and general practitioner

2012

Introduction: A general awareness of the most common genitourinary diseases is often lacking.The aim of the present study was to investigate the attention of the general practitioner and of the patient to the genitourinary diseases. An incomplete medical history and/or an inadequate physical examination might be responsible of late diagnosis and improper management. Patients and Methods: A self administered questionnaire was obtained by our outpatients before the urological visit. As a preliminary step we administered a very simple questionnaire consisting of four multiple choice questions: 1) Did your general practitioner examine your external genitalia in the last five years? Did you ask …

CORRELATION BETWEEN FIBRONECTIN GENE EXPRESSION AND LOCAL TOXICITY INDUCED BY ADJUVANT INTRAVESICAL THERAPY

2015

Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital.

2008

&lt;i&gt;Objectives:&lt;/i&gt; To investigate the safety and efficacy in terms of PSA response of a low-dose oral combination of estramustine phosphate (EMP) and etoposide (VP16) in hormone- refractory prostate cancer (HRPC) patients. Well-tolerated outpatient chemotherapy regimens for patients unfit and/or unwilling to be admitted to hospital are needed. &lt;i&gt;Methods:&lt;/i&gt; Fifty-six HRPC patients with metastatic disease (median age 75 years) were randomized between arm A (daily oral EMP 10 mg/kg, in 3 doses) and arm B (28-day cycle with low-dose EMP 3 mg/kg once daily plus VP16 25 mg/m&lt;sup&gt;2&lt;/sup&gt; once daily on days 1 through 14). Baseline characteristics between the t…

THE ROLE OF INTRAVESICAL GLYCOSAMINOGLYCANS IN TOXICITY INDUCED BY ADJUVANT INTRAVESICAL THERAPY: GENETIC LABORATORY EVIDENCE

2015

Environmental Risk Factors in Superficial Bladder Cancer

2004

As a preliminary approach to define the object of larger case-control studies, the distribution of potential risk factors coming from environmental pollution among patients affected by superficial bladder cancer (TCCB) has been analyzed. Material e Methods. The analysis included only patients affected by medium risk superficial TCCB. Forty Italian urological centres joined the study. Detailed information about age, sex, residency, employment, active and passive cigarette smoking, water resource, hair-dye use were centralized. All patients underwent TUR and early intravesical chemotherapy. The distribution of the above mentioned environmental factors was related to tumor characteristics suc…

Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma.

2003

To study GP-170 in superficial bladder cancer at initial diagnosis and at recurrence and to evaluate if intravesical chemoprophylaxis modifies the expression of GP-170 in tumor recurrences. GP-170 was retrospectively assessed in 160 patients affected by primary superficial transitional cell carcinoma of the bladder and followed for up to 10 years. Eighty-four patients (52.5%) recurred after transurethral resection (TUR). Adjuvant intravesical chemotherapy after TUR was adopted in 52 patients. The correlations between GP-170 and G-grade, T-category, risk of recurrence and of progression, and adoption of adjuvant intravesical chemotherapy were investigated. The correlations between variations…

Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder

2006

&lt;i&gt;Objective:&lt;/i&gt; The distribution of potential environmental risk factors among patients affected by superficial transitional cell carcinoma of the bladder (TCCB) has been analyzed. &lt;i&gt;Methods:&lt;/i&gt; Patients affected by superficial TCCB underwent TUR and early intravesical chemotherapy. Detailed data about age, sex, residence, employment, active and passive cigarette smoking, water resource and hair dye use were centralized. Analysis has been conducted on 474 patients affected by Ta-T1 G1-2 TCCB at medium risk for recurrence. Patients with primary single Ta G1-2, Tis or T1G3 tumors were excluded from the present analysis. &lt;i&gt;Results:&lt;/i&gt; Over 80% of the p…

The Multicriteria Electre III Model Applied to the Evaluation of the Placement of University Graduates

2010

During the last years the Italian university system has been undergoing a reform process regarding issues of governance such as the progressive financial autonomy of the University (art. 5, law 537/24 December 1993) and the reshape of the academic curricula (law 509/99 and 270/04). The most obvious result of this complex process has been the challenging attempt to manage a necessary change in a context of limited financial resources. In order to encompass the composite features of an efficient and effective management of resources, features of high relevance for the full accomplishment of the reform benchmarks, one has to take into account the academic organisation’s objectives, so that to …

A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-i…

2010

Study Type – Therapy (RCT) Level of Evidence 1b OBJECTIVE To evaluate the efficacy of 1-year maintenance after a 6-week cycle of early intravesical chemotherapy, as the role of maintenance in intravesical chemotherapy is debated. PATIENTS AND METHODS Between May 2002 and August 2003, 577 patients with non-muscle-invasive bladder cancer (NMI-BC) underwent transurethral resection (TUR) and early intravesical chemotherapy (epirubicin, 80 mg/50 mL). They were randomized between a 6-week induction cycle and the induction cycle plus maintenance with 10 monthly instillations. In all, 95 patients with T1G3, Tis or single and primary Ta–T1 G1–G2 tumours were excluded; 482 patients at intermediate ri…

CHOICE OF ADJUVANT INTRAVESICAL THERAPY IN RECURRING INTERMEDIATE-RISK NMI-BC

2011

Objective: The therapeutic strategy for patients affected by intermediate risk non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy is not definitively established. Only few studies have been published on secondline intravesical therapy. BCG is advocated when intravesical chemotherapy fails and is often repeated. On the other hand, some patients that suffer recurrence repeat intravesical chemotherapy. A retrospective analysis of 179 intermediaterisk patients submitted to second-line intravesical therapy is reported. Patients and Methods: The clinical files of patients affected by intermediate risk NMI-BC and submitted to second-line adjuvant intravesical therapy w…

VISCERAL FAT TISSUE ACTIVITY DOES NOT CORRELATE TO HIGH GRADE PROSTATE CANCER RISK AT BIOPSY

2015

Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cance…

2019

Abstract Background The aim of the study was to investigate the feasibility of Epidermal Growth Factor Receptor (EGFR) measurement in bladder washings of patients affected by non–muscle-invasive bladder cancer (NMIBC) and its prognostic role in identifying risk subgroups and predicting disease recurrence and progression. Patients and Methods Patients with NMIBC treated with transurethral resection of bladder tumor (TURBT) from 2012 to 2015 were enrolled. Samples of bladder washings were collected and stored at −80°C until RNA extraction. The cDNA obtained from RNA was used to perform a gene expression analysis by a real time polymerase chain reaction. Results An adequate cellular pellet was…

RE-TREATMENT BY INTRAVESICAL THERAPY IN RECURRING PATIENTS AFFECTED BY INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMI-BC)

2011

Introduction & Objectives: Up to 70% of patients affected by intermediate risk NMI-BC recur after intravesical therapy (IT). The majority of them will be retreated by IT. The therapeutic strategy for these patients is not well defined. BCG is advocated when intravesical chemotherapy (ICH) fails. However, some patients are retreated by ICH and some others repeat BCG adopted as the first treatment. Not many studies have been published on second line IT. A retrospective analysis on 179 intermediate-risk patients undergoing re-treatment by IT is presented. Materials & Methods: The clinical files of patients affected by NMI-BC recurring after TUR and IT and retreated by IT were reviewed. The pat…

Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder: Phase I-II study on marker lesions

2004

Abstract Objectives To study the ablative activity of intravesical gemcitabine against superficial transitional cell carcinoma of the bladder at different doses and concentrations. Methods A total of 27 patients were treated with intravesical gemcitabine after transurethral resection during which one to three papillary marker lesions were left unresected. Starting 14 days after transurethral resection, six instillations of gemcitabine were given at weekly intervals. Gemcitabine, diluted in 50 mL of saline solution and maintained for 2 hours, was given at the dose of 500 mg, 1000 mg, and 2000 mg in groups of 9 patients each. A complete response (CR) was defined as negative cytology, cystosco…

University Performance Before and During Economic Crises. An Analysis of Graduate Characteristics

2020

The aim of this book is to analyze the performance of some Italian universities during a pre-crisis period and an economic crisis period, on the basis of graduate characteristics and graduate placement statistics. The Electre model is used to produce eighteen university rankings according to three different scenarios (Neutral, University and Job), three different roles ascribed to the key criteria (overeducation and mismatching), and two years corresponding to two postgraduation placement sampling surveys carried out in a pre-crisis period (2006) and during a crisis period (2011). The eighteen rankings are based on Economics/Statistics and Political &amp; Social Sciences graduates. The rank…

Out-patient low-dose oral chemotherapy in hormone refractory prostate carcinoma (HRPC) patients unfit for hospital admittance.

2008

Objectives: Well tolerated out-patient regimens for HRPC chemotherapy in elderly patients with geographical difficulties and/or unwilling hospital admission are needed. The aim of the present study was to investigate the safety and efficacy of a low-dose oral combination of estramustine phosphate (EMP) and etoposide (VP16). Patients: Fifty-six HRPC patients, median age 75 years, were randomized between daily EMP (10mg/kg) – arm A, and low-dose EMP (3mg/kg) plus VP16 (25mg/mq) 2 weeks monthly – arm B. Randomization ratio was 2:3. Median PSA was 41.1 ng/ml. Baseline characteristics between the 2 groups were similar. LHRH therapy was maintained. Antiandrogen was stopped one month before entry.…

TUR and Adjuvant Intravesical Chemotherapy in T1G3 Bladder Tumors: Recurrence, Progression and Survival in 137 Selected Patients Followed Up to 20 Ye…

2003

Abstract OBJECTIVES: To evaluate a highly selected population of patients affected by T1G3 bladder transitional cell carcinoma (TCCB) treated by transurethral resection (TUR) and adjuvant intravesical chemotherapy. MATERIALS AND METHODS: Between January 1976 and April 1999, 137 patients with T1G3 TCCB were treated by TUR plus intravesical chemotherapy. Particularly, a sequential combination of mitomycin C (MMC) and epirubicin (EPI) was adopted in 91 patients (66.4%). The main exclusion criteria were concomitant or previous Tis, previous T1G3 TCCB, tumor size greater than 3 centimeters and number of tumors more than 3. TUR was repeated if a superficial tumor recurred. Patients went off study…

PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients

2007

Microscopic foci of prostatitis may induce prostate-specific antigen (PSA) increase. PSA reduction after antibiotics might identify those patients in whom biopsy can be avoided. Ninety-nine patients received ciprofloxacin for 3 weeks, of whom 59 showed PSA reduction. Histology detected small foci of prostatitis in 65% of cases. Carcinoma was found in 40 and 20.3% of patients with unchanged or decreased PSA, respectively (P=0.03). No cancer was detected if PSA decreased below 4 ng/ml or more than 70%. Biopsy can be postponed, with a low risk of missing a cancer, if PSA decreases more than 70% or below 4 ng/ml.

Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Nonemuscle-invasive Bladder Carcinoma

2013

Objective To study the effect of smoking status at diagnosis on recurrence in intermediate-risk non–muscle-invasive bladder carcinoma treated by transurethral resection (TUR) of the bladder and early intravesical chemotherapy. Methods Tumor characteristics and smoking status were recorded in 395 patients entered in a randomized multicenter trial comparing 2 different schedules of early intravesical chemotherapy. All patients received intravesical epirubicin (80 mg/50 mL) within 6 hours after TUR, followed by 5 more weekly instillations with (arm B) or without (arm A) monthly instillations for 1 year. Smoking habit was investigated at diagnosis through a structured questionnaire. Multivariat…

Medial tunica degeneration of the ascending aortic wall is associated with specific microRNA changes in bicuspid aortic valve disease

2021

Ascending aortic diameter is not an accurate parameter for surgical indication in patients with bicuspid aortic valve (BAV). Thus, the present study aimed to identify specific microRNAs (miRNAs/miRs) and their expression levels in aortic wall aneurysm associated with BAV according to severity of medial degeneration and to elucidate the association between the tissue expression levels of the miRNAs with their expression in plasma. Aortic wall and blood specimens were obtained from 38 patients: 12 controls and 26 patients with BAV with ascending aortic aneurysm. Of the patients with BAV, 19 had cusp fusions of right and left, 5 of right and non-coronary, and 2 of left and non-coronary. Two gr…

A RANDOMISED STUDY EVALUATING MAINTENANCE SCHEDULE IN EARLY ADJUVANT CHEMOTHERAPY FOR INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER

2008

ABSTRACT Introduction and Objective: Adjuvant intravesical chemotherapy or BCG immunotherapy after transurethral resection (TUR) is a standard treatment for non–muscle-invasive transitional cell cancer of the bladder (NMI TCCB) at intermediate risk. Although the clinical value of early intravesical adjuvant chemotherapy is well established, the optimal schedule regimen and the role of maintenance is still debated. Methods: Between May 2002 and August 2003, 577 patients, undergoing TUR for NMI TCCB, were recruited. All patients underwent TUR and early (within 6 hours) intravesical chemotherapy with epirubicin at the dose of 80 mg diluted in 60 ml of saline solution. When histology was availa…

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy

2015

Context: The therapeutic strategy in intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy (IT) is not well defined. Most patients are usually retreated by Bacillus Calmette-Guerin (BCG). Aims: To evaluate the efficacy of intravesical chemotherapy (ICH) given at recurrence after the first cycle of ICH in IR-NMIBC recurring 6 months or later. Settings and Design: Retrospective analysis of the efficacy of ICH given after previous IT. Materials and Methods: The clinical files of IR-NMIBC patients recurring later than 6 months after transurethral resection (TUR) and IT and retreated by IT were reviewed. The patients should be at intermediate risk…

Cigarette Smoking and Drinking Water Source: Correlation with Clinical Features and Pathology of Superficial Bladder Carcinoma

2007

&lt;i&gt;Objective:&lt;/i&gt; Water source and cigarette smoking are related to clinical characteristics and pathology of superficial transitional cell carcinoma of the bladder. &lt;i&gt;Methods:&lt;/i&gt; Tumor number, dimension, G-grade, T-stage, recurrences, cigarette smoking and water supply were recorded in patients harboring Ta–T1 G1–3 transitional cell carcinoma of the bladder. &lt;i&gt;Results:&lt;/i&gt; Of 577 patients, 61% had multiple and 36% recurrent tumors. Two hundred and forty-one patients (42%) were current smokers and 188 (33%) were former smokers. Bottled water was the only drinkable source for 249 (45%) patients, municipal water supply for 177 (32%), artesian wells for 3…

Modificazioni del PSA dopo terapia antibiotica in pazienti candidati alla biopsia prostatica.

2005

Water Chlorination and other environmental factors in bladder cancer. Result of a multicentre study.

2005

Il carcinoma prostatico in Sicilia e Calabria. età, stadiazione e PSA alla diagnosi

2004

Chemioterapia adiuvante nei tumori vescicali non muscolo invasivi a rischio intermedio. Risultati preliminari di uno studio retrospettivo multicentri…

2011

Introduzione e obiettivi Malgrado la chemioprofilassi endovescicale precoce dopo TUR sia indicata dalle linee guida in tutti i pazienti affetti da tumore vescicale non muscolo invasivo (NMI-BC), ancora dubbio rimane il miglior regime di terapia endovescicale adiuvante nei pazienti affetti da NMI-BC a rischio intermedio. Recenti studi sostengono l’adozione ab inizio del BCG. Vengono presentati i risultati preliminari di uno studio retrospettico multicentrico teso ad analizzare l’efficacia della chemioprofilassi endovescicale in questa categoria di pazienti e i diversi fattori che possono interferire sulla sua azione. Materiali e metodi Sono stati inseriti nello studio solo pazienti gia selez…

Analisi preliminare dei fattori demografici ed eziopatogenetici in pazienti affetti da carcinoma vescicale a medio rischio di recidiva

2004

FOLLOW UP A LUNGO TERMINE DI PAZIENTI CON POSITIVITA’ DELLA NMP22 E NEGATIVITA’ CISTOSCOPICA E CITOLOGICA

2005

TERAPIA DI II LINEA NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO (HRPC) CON ESTRAMUSTINA FOSFATO ED ETOPOSIDE. STUDIO DI FASE II DEL GSTU

2005

Predictive value of positive NMP22 in patients with negative cytology and cystoscopy.

2010

Diagnosi precoce del carcinoma prostatico in sicilia e calabria. Dati preliminare di uno studio osservazionale del GSTU e della SSCU.

2004

Fattori di rischio ambientale nel carcinoma vescicale superficiale. Risultati su 577 pazienti sottoposti a chemioterapia endovescicale adiuvante.

2005

STUDIO RANDOMIZZATO SUL RUOLO DEL MANTENIMENTO NELLA CHEMIOPROFILASSI ENDOVESCICALE PRECOCE DOPO TUR CON EPIRUBICINA

2006

VALUTAZIONE DELLA TERAPIA A LUNGO TERMINE CON TADALAFIL IN PZ CON DISFUNZIONE ERETTILE: UPDATE DOPO 6 MESI

2006

Introduzione e obiettivi Caratterizzare, in uno studio prospettico longitudinale su pazienti (pz) con disfunzione erettile (DE) trattati per 6 mesi con Tadalafil (Tad), efficacia, sicurezza, e grado di soddisfazione per il trattamento del pz e della partner. Materiali e metodi Furono arruolati 155 pz (età media 67 anni, range 26-75) con DE, mai trattati (naïve) nel 74% dei casi. La DE, presente da 2 (10%). Del piano terapeutico previsto (totale 9 m) (posologia Tad: iniziale, costante, 20 mg x 2/sett. x 6 m.; proseguimento: 20 mg x 1-2/sett. x altri 3 m. in base a risposta dei primi 6 m. e/o opzione motivata dal pz) riportiamo i dati su efficacia (IIEF5) e soddisfazione (EDITS-paziente; EDIT…

ESTRAMUSTINA FOSFATO VS ASSOCIAZIONE A BASSA DOSE DI ESTRAMUSTINA FOSFATO E ETOPOSIDE NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO (HRPC). STUDIO RANDO…

2006

-

Efficacy of one-year maintenance in early adjuvant chemotherapy for intermediate risk non-muscle-invasive bladder cancer. Preliminary results of a ra…

2008

Introduction and Objective: The clinical value of early intravesical adjuvant chemotherapy after TUR of intermediate risk non-muscle-invasive bladder cancer (NMI TCCB) is well established. On the other hand, the optimal schedule regimen and the role of maintenance are still debated. The aim of the present study was to evaluate the effectiveness of one-year maintenance schedule in patients submitted to TUR plus adjuvant early intravesical chemotherapy. Methods: Between May 2002 and August 2003, 577 patients, were recruited. All patients underwent TUR and early (within 6 hours) intravesical chemotherapy with epirubicin at the dose of 80 mg diluted in 60 ml of saline solution. When histology w…

Fattori di rischio ambientale nel carcinoma vescicale superficiale. Risultati su 577 pazienti sottoposti a chemioterapia endovescicale adiuvante

2006

Ruolo della terapia di mantenimento e fattori di rischio ambientale nel carcinoma vescicale superficiale. Pazienti sottoposti a chemioterapia endoves…

2005

Environmental factors in superficial bladder cancer. Preliminary report of a prospective study

2004

Chemioterapia domiciliare nel carcinoma prostatico ormonorefrattario (HRPC). Studio di fase II del gruppo studio tumori urologici (GSTU).

2005

Studio randomizzato sul ruolo del mantenimento nella chemioprofilassi endovescicale precoce dopo TUR con Epirubicina. XVI Congresso Nazionale Società…

2006

Cigarette smoking and drinking water source: Correlation with clinical features and pathology of superficial bladder carcinoma.

2009

Efficacia del mantenimento nella chemioprofilassi endovescicale precode dopo TUR. Risultati di uno studio randomizzato multicentrico.

2007

CHEMIOPROFILASSI PRECOCE CON EPIRUBICINA AD ALTA DOSE NEL CARCINOMA VESCICALE SUPERFICIALE. STUDIO RANDOMIZZATO DEL GSTU

2006

Risultati a lungo termine del trattamento con TUR e terapia endovescicale adiuvante nell’urotelioma vescicale T1G3. Recidiva, progressione e sopravvi…

2007

Studio randomizzato multicentrico: mantenimento mensile per un anno versus induzione per 6 settimane nella chemioprofilasi precoce dopo TUR.

2007

IS IT POSSIBLE TO PREDICT CHEMORESISTANCE OF SUPERFICIAL BLADDER CARCINOMA?

2004

Prostatite clinicamente silente (INH IV) ed elevazione del PSA.

2006

TERAPIA CONSERVATIVA CON TUR E TERAPIA ENDOVESCICALE ADIUVANTE IN UNA POPOLAZIONE SELEZIONATA DI PAZIENTI AFFETTI DA CARCINOMA VESCICALE T1G3

2004

"LUTS E DE NELLA PRATICA CLINICA ANDROLOGICA IN SICILIA: ANALISI EPIDEMIOLOGICA SU CONDIZIONI DI FAMILIARITA' (PATOLOGIE URO-GENITALI), COMORBIDITA',…

2009

Il regime di mantenimento potenzia l’efficacia della chemioprofilassi endovescicale precoce e induzione settimanale nei confronti delle recidive degl…

2008

SCOPO DEL LAVORO: Malgrado l’efficacia della chemioterapia endovescicale eseguita precocemente dopo la resezione endoscopica di uroteliomi vescicali NMI sia stata confermata da numerosi studi multicentrici, ancora dubbio rimane il ruolo di un ulteriore schema terapeutico di mantenimento nel potenziarne l’efficacia. Ciò rimane ancora più incerto se alla singola instillazione segue un ciclo di instillazioni settimanali. Scopo dello studio è stato valutare l’utilità di uno schema di mantenimento mensile per un anno rispetto alla sola induzione settimanale per 6 settimane in pazienti sottoposti a TUR e chemioprofilassi precoce con epirubicina. MATERIALI E METODI: Sono stati randomizzati 577 paz…

Terapia orale domiciliare per il paziente con il carcinoma prostatico ormonorefrattario.

2008

TERAPIA ORALE DOMICILIARE PER IL PAZIENTE CON CARCINOMA PROSTATICO ORMONOREFRATTARIO V. Altieri, V. Serretta, D. Melloni, R. Allegro, G. Morgia, M. Madonia, M. Ferro, A. Siragusa, G. De Grande, L. Orestano, M. Napoli, E. Membri Fondazione GSTU (Napoli) SCOPO DEL LAVORO: Per preservare la qualità di vita del paziente affetto da carcinoma prostatico ormonorefrattario (HRPC) si rendono necessari regimi terapeutici che possano essere eseguiti a domicilio senza frequenti ricoveri ospedalieri, seppur in regime di dayhospital. I vantaggi in termini di sopravvivenza offerti da schemi chemioterapici a base di taxani, pur presenti, sono ad oggi limitati. Scopo del presente studio di fase II è stato q…

ESTRAMUSTINA FOSFATO VS ASSOCIAZIONE A BASSA DOSE DI ESTRAMUSTINA FOSFATO ED ETOPOSIDE NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO. STUDIO RANDOMIZZAT…

2005

Terapia della patologia mammaria indotta da antiandrogeno puro. Risultati di uno studio randomizzato.

2007

La p53 nel tumore vescicale superficiale (Ta-T1, G1-3)

2004

LA RIDUZIONE DEL PSA DOPO TERAPIA ANTIBIOTICA NON HA VALORE PREDITTIVO IN SOGGETTI CANDIDATI ALLA AGOBIOPSIA PER SOSPETTO TUMORE PROSTATICO T1C

2005

Aspetti del capitale sociale e umano all’Albergheria

2006

Le condizioni socio-economiche all'Albergheria

2006

ESTRAMUSTINE PHOSPATE VERSUS INTERMITTENT LOW DOSE ORAL COMBINATION OF ESTRAMUSTINE PHOSPATE AND ETOPOSIDE IN HORMONE REFRACTORY PROSTATE CARCINOMA. …

2006

POSITIVITA’ DELL’NMP22 E NEGATIVITA’ CISTOSCOPICA E CITOLOGICA. QUALE SIGNIFICATO ATTRIBUIRE?

2005

Fumo, risorsa idrica ed altri fattori di rischio nel carcinoma vescicale superficiale

2004

Drinking water source and cigarette smoking in transitional cell carcinoma of the bladder.

2006

OBJECTIVE: Water source and cigarette smoking are related to clinical characteristics and pathology of superficial transitional cell carcinoma of the bladder. METHODS: Tumor number, dimension, G-grade, T-stage, recurrences, cigarette smoking and water supply were recorded in patients harboring Ta-T1 G1-3 transitional cell carcinoma of the bladder. RESULTS: Of 577 patients, 61% had multiple and 36% recurrent tumors. Two hundred and forty-one patients (42%) were current smokers and 188 (33%) were former smokers. Bottled water was the only drinkable source for 249 (45%) patients, municipal water supply for 177 (32%), artesian wells for 38 (7%), spring water for 7 (1%) and mixed source for 89 (…

Survival risk factors in T1G3 non-muscle-invasive (NMI) bladder cancer consevatively treated. Long term results.

2008

Introduction: The most relevant risk factor in T1G3 NMI transitional cell carcinoma of the bladder (TCCB) is the presence of Tis. The long term results of conservative management still are a matter of controversy. The role of BCG in preventing progression and death in this category of NMI TCCB is not definitely proved. The published experiences of conservative treatment of high risk TCCB often include unselected patients, small numbers and short follow-up. Immediate radical cystectomy is advocated by many urologists. Objectives: The aim of the study is to identify the survival risk factors in 236 selected patients conservatively treated. Methods: Between January 1976 and December 2005, 236 …

SMOKING STATUS, RECURRENCE RISK AND INTRAVESICAL CHEMOTHERAPY IN NONMUSCLE- INVASIVE BLADDER CANCER

2011

Background and Aim: The influence of smoking status on the diagnosis of carcinoma of the bladder, on recurrence risk Abstracts of the 21st Annual Meeting of the Italian Society of Uro-Oncology (SIUrO), 22-24 June, 2011, Naples, Italy and response to intravesical treatment has been scarcely studied. Available studies suggest a reduction in recurrence risk with cessation of smoking, however, most studies lack sufficient statistical power. The aim of the present analysis was to study the recurrence risk and the response to intravesical chemotherapy in terms of recurrence-free rate (RFR) and recurrence-free survival (RFS) in relation to smoking status at diagnosis in patients affected by interm…

Fumo di sigaretta e risorsa idrica in pazienti affetti da carcinoma vescicale superficiale. XV Congresso Nazionale SIUro, Giardini Naxos 3-6 novembre…

2005

low dose oral chemotherapy for hormone refractory prostate carcnoma.Estramustine phosphate versus estramustine phosphate and etoposide. A randomised …

2006

Fattori di rischio ambientali nella storia naturale del carcinoma vescicale superficiale.

2004

Role of antimicrobial tratment in patients with elevated PSA and normal digital rectal examination.

2006

Il carcinoma prostatico in Calabria e Sicilia.

2004

Significato clinico della positività della NMP22 in pazienti in follow-up per carcinoma vescicale superficiale. Risultati a lungo termine

2005

Tamoxifene nella mastopatia da bicalutamide. Risultati preliminari di uno studio randomizzato: profilassi versus terapia alla comparsa.

2007

Ruolo prognostico della p53 nel tumore vescicale superficiale. Correlazione con recidiva e progressione –

2005

-

TERAPIE CONSERVATIVA DELL'UROTELIOMA VESCICALE T1G3. RISULTATI SU 235 PAZIENTI

2006

Studio retrospettico esteso ad oltre 20 anni su BCG o chemioterapia endovescicale in pazienti selezionati affetti da urotelioma vescicale T1G3. Recid…

2007

Is the efficacy of intravescical chemotherapy influenced by cigarette smoking? Data obtained in intermediate risk non muscle invasive bladder carcino…

2011

Aim of the study To study recurrence-free rate (RFR) and recurrence-free survival (RFS) according to the smoking status in patients affected by non-muscle invasive carcinoma of the bladder (NMI-BC) treated by intravesical chemotherapy. Materials and methods Smoking status was recorded at study entry. Intravesical epirubicin was administered within 6 hours from TUR at the dose of 80 mg diluted in 50 ml of saline solution. Further adjuvant treatment in low-risk and high-risk patients was given according to physicians’ choice. The remaining patients, at intermediate risk for recurrence, were randomized between two different schemes of intravesical chemotherapy: 5 more weekly instillations (tot…

Uno sguardo alle famiglie

2006

Significato clinico della positività della NMP22 in pazienti in follow-up per carcinoma vescicale superficiale. Risultati a lungo termine

2006

Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma. Twelve-year’s results of a phase II study.

2003

OBJECTIVE: To present the long-term outcome of patients with locally advanced or metastatic prostate carcinoma treated by first-line antiandrogen monotherapy. PATIENTS AND METHODS: From 1983 to 1990, 41 patients with advanced prostate carcinoma were treated with flutamide monotherapy until progression or the appearance of toxicity. Twenty-five patients (61%) had T3-T4N0M0 and 16 (39%) T2-4N0-3M1 prostate carcinoma. Consensus criteria were adopted to evaluate the response. Plasma testosterone and sexual function were recorded for the first 3 years. RESULTS: Flutamide was administered for up to 147 months; seven patients (17%) interrupted the treatment because of toxicity. There was an object…

Diagnosi precoce del carcinoma prostatico in Sicilia e Calabria. Dati preliminari di uno studio osservazionale del GSTU e della SSCU

2004

“Analysis of serum HER-2/neu levels (S-HER2) in breast cancer (BC) patients (pts)”

2006

Single dose prulifloxacina can improve BCG tollerability

2010

Tossicità e mantenimento nella chemioprofilassi endovescicale precoce (entro 6 ore) dopo TUR di carcinoma vescicale superficiale.

2006

Chemioterapia adiuvante e fattori di rischio ambientale nel carcinoma vescicale superficiale a medio rischio di recidiva. Uno studio prospettico rand…

2004

Adjuvant intravesical therapy in intermediate risk non-muscle invasive bladder cancer (NMIBC) recurring after first cycle of intravesical treatment.

2011

Introduction and objectives The therapeutic management of intermediate risk NMI-BC recurring after intravesical therapy (IT) is not established. Cystectomy will be offered to patients at higher risk of progression but the majority will be retreated by IT. Although some Authors suggest BCG when intravesical chemotherapy (ICH) fails, some patients are retreated by ICH and some others repeat BCG adopted as first-line treatment. Not many studies have been published on this issue. The response to retreatment by intravesical therapy in terms of recurrence-free rate (RFR) and recurrence-free survival (RFS) is analyzed in 179 intermediate-risk patients. Materials and methods Only intermediate-risk …

TERAPIA CONSERVATIVA DELL'UROTELIOMA VESCICALE T1G3. RISULTATI SU 235 PAZIENTI

2006

Valore clinico della riduzione del PSA in soggetti candidati all’agobiopsia prostatica

2004

Distribution of smoking, water resource and other environmental factors in patients affected by superficial bladder cancer

2004

INTRODUCTION AND OBJECTIVE: The pathogenetic role cancer of sigarette smoking and employment in bladder has been studied, however, that of other environmental factors is not well defined. Case-control studies require high numbers and are expensive. As a preliminary approach to larger case-control studies, the distribution of potential risk factors coming from environmental pollution among patients affected by superficial bladder cancer (TCCB) has been prospectively analized.